Novak & Powell Financial Services Inc. Has $1.95 Million Stock Holdings in Johnson & Johnson $JNJ

Novak & Powell Financial Services Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 35.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,488 shares of the company’s stock after buying an additional 2,754 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of Novak & Powell Financial Services Inc.’s portfolio, making the stock its 20th biggest position. Novak & Powell Financial Services Inc.’s holdings in Johnson & Johnson were worth $1,945,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Abich Financial Wealth Management LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $26,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $28,000. Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc increased its stake in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $243.03 on Tuesday. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The company has a market cap of $585.37 billion, a P/E ratio of 21.99, a P/E/G ratio of 2.38 and a beta of 0.34. The firm has a 50-day moving average of $232.69 and a 200-day moving average of $207.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Citigroup boosted their target price on shares of Johnson & Johnson from $250.00 to $274.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. HSBC lifted their price target on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Sanford C. Bernstein increased their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $235.91.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.